CVS Health Files 8-K Report

TL;DR

CVS Health filed an 8-K on 11/20/25. No major news, just standard disclosures.

AI Summary

CVS Health Corporation filed an 8-K report on November 20, 2025, to disclose information regarding other events and financial statements. The filing does not contain specific details about new transactions, material events, or financial figures within the provided text.

Why It Matters

This 8-K filing indicates that CVS Health is providing updates or disclosures to the SEC, which could be relevant for investors monitoring the company's regulatory compliance and corporate actions.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report without specific material events or financial disclosures that would immediately impact risk.

Key Players & Entities

• CVS HEALTH Corp (company) — Registrant
• November 20, 2025 (date) — Date of report
• Delaware (jurisdiction) — State of incorporation
• 001-01011 (identifier) — Commission File Number
• 05-0494040 (identifier) — I.R.S. Employer Identification No.
• One CVS Drive Woonsocket, Rhode Island 02895 (address) — Principal Executive Offices
• (401) 765-1500 (phone_number) — Registrant's Telephone Number

FAQ

From the Filing

0001193125-25-289805.txt : 20251120 0001193125-25-289805.hdr.sgml : 20251120 20251120161811 ACCESSION NUMBER: 0001193125-25-289805 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20251120 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20251120 DATE AS OF CHANGE: 20251120 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CVS HEALTH Corp CENTRAL INDEX KEY: 0000064803 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-DRUG STORES AND PROPRIETARY STORES [5912] ORGANIZATION NAME: 07 Trade & Services EIN: 050494040 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-01011 FILM NUMBER: 251503255 BUSINESS ADDRESS: STREET 1: ONE CVS DR. CITY: WOONSOCKET STATE: RI ZIP: 02895 BUSINESS PHONE: 4017651500 MAIL ADDRESS: STREET 1: ONE CVS DR. CITY: WOONSOCKET STATE: RI ZIP: 02895 FORMER COMPANY: FORMER CONFORMED NAME: CVS CAREMARK CORP DATE OF NAME CHANGE: 20070509 FORMER COMPANY: FORMER CONFORMED NAME: CVS/CAREMARK CORP DATE OF NAME CHANGE: 20070322 FORMER COMPANY: FORMER CONFORMED NAME: CVS CORP DATE OF NAME CHANGE: 19970128 8-K 1 d172430d8k.htm 8-K 8-K CVS HEALTH Corp false 0000064803 0000064803 2025-11-20 2025-11-20     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 20, 2025       CVS HEALTH CORPORATION (Exact Name of Registrant as Specified in Charter)       Delaware   001-01011   05-0494040 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.) One CVS Drive Woonsocket , Rhode Island 02895 (Address of Principal Executive Offices, and Zip Code) (401) 765-1500 Registrant’s Telephone Number, Including Area Code N/A (Former name, former address and former fiscal year, if changed since last report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.01 per share   CVS   New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 8.01. Other Events. Appointment of J. David Joyner as Chair of the Board of Directors On November 20, 2025, the Board of Directors (the “Board”) of CVS Health Corporation (the “Company”) appointed J. David Joyner, President and Chief Executive Officer of the Company, to the additional role of Chair of the Board, effective January 1, 2026. Following the effective date of this appointment, Michael F. Mahoney will continue to serve as the Boa